XpresSpa Group Announces the Opening of XpresCheck COVID-19 Testing Facility at Newark Liberty International Airport’s Terminal B on August 17, 2020

New Site Builds on Pilot Program at JFK International Airport’s Terminal 4

Terminal B Can Provide 350 COVID-19 Tests per Day for EWR Airport Workers

NEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced, in conjunction with the Port Authority of New York and New Jersey, the opening of the XpresCheck at Newark Liberty International Airport’s Terminal B on August 17, 2020.

In its initial phase, testing will be available to EWR terminal employees, airline employees, and airport workers through an expanded contract with XpresSpa’s new brand, XpresCheck. The new facility has the capacity to screen up to 350 airport employees per day. Following this initial launch period, testing at EWR’s XpresCheck site is expected to be made available to passengers.

“Across the agency, we have employed various preventive measures to ensure the safety of travelers and airport personnel and are continually exploring ways to further enhance these measures,” said Kevin O’Toole, Port Authority Chairman. “We remain committed to implementing additional measures and policies, as well as expanding and exploring various pilots, such as this new on-airport testing site, to further safeguard those at our facilities.”

“The Port Authority has taken proactive measures to provide a safe environment for both employees and customers, including piloting a partnership with XpresCheck to bring testing right into our airport terminals,” said Rick Cotton, Port Authority Executive Director. “We look forward to seeing the results of the pilot at Newark Liberty and to further conversations with XpresCheck. We hope to see testing capability expand as widely as possible.”

XpresCheck, which began as a pilot at John F. Kennedy International Airport, was one of the first COVID-19 testing locations at a U.S. airport. The JFK site, which is managed by JFK-IAT and XpresCheck’s parent company XpresSpa, is now open to passengers in addition to airport employees for testing.    

Similar to the site in JFK’s Terminal 4, the EWR testing site is a new modular site constructed on Level 3 in Terminal B. It provides six separate testing rooms and is capable of conducting both COVID-19 testing and antibody testing. These services will be available to all airport employees, including airline employees, contractors and workers, concessionaires and their employees, TSA officers, and U.S. Customs and Border Protection (CPB) agents. Both antibody testing and polymerase chain reaction (PCR) testing are available on-site, and the tests are sent to outside laboratories. All insurance plans are accepted outside of network and all information will remain private and HIPAA-compliant.